Connection | Profiles RNS

Login to edit your profile (add a photo, awards, links to other websites, etc.)

Search Result Details

Back to Search Results

This page shows the details of why an item matched the keywords from your search.

Search Results

MERIC-BERNSTAM, FUNDA

One or more keywords matched the following items that are connected to MERIC-BERNSTAM, FUNDA

Item Type	Name
Concept	Cholangiocarcinoma
Academic Article	Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications.
Academic Article	Mutation profiling in cholangiocarcinoma
Academic Article	Biliary cancer: Utility of next-generation sequencing for clinical management.
Academic Article	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
Academic Article	Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients.
Academic Article	The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.
Academic Article	Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study.
Academic Article	Cholangiocarcinoma With FGFR Genetic Aberrations: A Unique Clinical Phenotype.
Academic Article	Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors.
Academic Article	Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines.
Academic Article	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma.
Academic Article	Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Academic Article	Convergent MAPK pathway alterations mediate acquired?resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma.
Academic Article	First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

Search Criteria

Cholangiocarcinoma